Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of$ 0.25. This compares to loss of $0.25 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -4%. A quarter ago, it was expected that this molecular diagnostic company would post a loss of$ 0.25 per share when it actually produced a loss of $0.22, delivering a surprise of 12%. Over the last four quarters, the co ...